1
TÍTULO: Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
AUTORES: Fritz Offner; Olga Samoilova; Evgenii Osmanov; Hyeon Seok Eom; Max S Topp; Joao Raposo; Viacheslav Pavlov; Deborah Ricci; Shalini Chaturvedi; Eugene Zhu; Helgi van de Velde; Christopher Enny; Aleksandra Rizo; Burhan Ferhanoglu;
PUBLICAÇÃO: 2015, FONTE: BLOOD, VOLUME: 126, NÚMERO: 16
INDEXADO EM: Scopus WOS CrossRef
2
TÍTULO: Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab
AUTORES: Bertrand Coiffier; Weimin M Li; Erin D Henitz; Jayaprakash D Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A Elsayed; Helgi van de Velde; Michael E Schaffer; Evgenii A Osmanov; Xiaonan N Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko Jarosinska; Sven de Vos; Michael Crump; Ofer Shpilberg; Pier Luigi Zinzani; Andrew Cakana; Dixie Lee Esseltine; George Mulligan; Deborah Ricci; ...Mais
PUBLICAÇÃO: 2013, FONTE: CLINICAL CANCER RESEARCH, VOLUME: 19, NÚMERO: 9
INDEXADO EM: Scopus WOS CrossRef
3
TÍTULO: A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma
AUTORES: Bertrand Coiffier; Evgenii Osmanov; Xiaonan N Hong; Adriana Scheliga; Jiri Mayer; Fritz C Offner; Simon A Rule; Adriana Teixeira; Jan A Walewski; Michael Crump; Ofer Shpilberg; Robert Hermann; Sudha Parasuraman; Eugene Zhu; Christopher Enny; Panteli Theocharous; Helgi van de Velde; Yusri Elsayed; Pier Luigi Zinzani;
PUBLICAÇÃO: 2010, FONTE: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) in BLOOD, VOLUME: 116, NÚMERO: 21
INDEXADO EM: WOS